Press Releases
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with Circular Genomics for the Transformative Bio-Hermes-001 Study
Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data Washington D.C., May 28, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Circular Genomics, a biotechnology company revolutionizing neurological and psychiatric precision medicine, access to analyze Bio-Hermes-001 samples to investigate the potential for circular RNA […]
Alzheimer’s Research Sites Honor National Clinical Trials Day
Free Memory Screenings Offered to Promote Importance of Brain Health WASHINGTON, DC (May. 20, 2026)- Alzheimer’s research sites across the country are honoring National Clinical Trials Day by offering free memory screening for adults age 55 and older. National Clinical Trials Day recognizes the progress made in developing treatments and therapies, advances which could not have been […]
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership for the Transformative Bio-Hermes-002 Study
Bio-Hermes-002 is a collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias. Washington D.C., May 18, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce the continued expansion of the Bio-Hermes-002 study, a unique observational platform study, which evaluates blood-based and digital biomarkers across a wide spectrum of cognitive conditions, alongside MRI and PET imaging and diverse […]
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with Siemens Healthineers for the Transformative Bio-Hermes-002 Study
Siemens Healthineers joins collaborative study focused on new biomarkers designed to improvediagnosis of Alzheimer’s disease and dementias Washington D.C., Apr. 9, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare, to the Bio-Hermes-002 study. This collaboration will enhance this unique, […]
Axiom Brain Health’s Dr. Susan Steen to be Honored at Inspire, Imagine, and Hope Gala on Friday
Tampa, FL, Mar 25, 2026— Axiom Brain Health (Axiom) is pleased to announce Dr. Susan Steen will be honored by the Alzheimer’s Association – Florida Gulf Coast Chapter at the Inspire, Imagine, and Hope Gala on Friday, March 27, 2026, at The Gathering @ Armature Works in Tampa. “I am delighted to receive this honor from the […]
Exceptional Clinical Trial Volunteers Presented National Citizen Scientist Awards for Research Efforts
The Global Alzheimer’s Platform Foundation’s® (GAP) 2025 Citizen Scientist Award® recipients announced in Las Vegas WASHINGTON, DC (Feb. 27, 2026) — Today, the Global Alzheimer’s Platform Foundation (GAP) proudly announced the 2025 National Citizen Scientist Awards® elevated honorees. GAP’s Citizen Scientist Awards (CSA) acknowledge the contributions of individuals who make a difference by volunteering in clinical trials for neurodegenerative diseases. This year’s award […]
Leading Alzheimer’s Experts to Convene in Las Vegas at International Clinical Research Conference
Researchers and Executives from almost 50 clinical trial sites, pharmaceutical companies and technology partners to collaborate on improving research & treatment options Las Vegas., Feb. 20, 2026- From February 25 through February 27 the Global Alzheimer’s Platform Foundation® (GAP), an organization dedicated to speeding and improving the delivery of Alzheimer’s and neurodegenerative clinical trials in pursuit of a cure, will convene nearly 250 representatives from […]
GAP Statement on “Interchangeability of blood-based biomarkers and PET to identify Alzheimer’s disease pathology”
“Changes in memory and cognitive health can start decades before symptoms appear. That’s why early diagnosis and intervention are crucial to slowing impact. A new paper co-authored by GAP with our partners at Eli Lilly and Company, “Interchangeability of blood-based biomarkers and PET to identify Alzheimer’s disease Pathology” published in Alzheimer’s & Dementia shows that blood biomarkers (P-tau 217 and Precivity AD) have high agreement with […]
GAP Statement on Recent Bio-Hermes-001 Publication in Alzheimer’s & Dementia
“We’re pleased and proud to report our latest paper using Bio-Hermes-001 data has been published in Alzheimer’s & Dementia. Many thanks to the co-authors who helped to bring this research article to light including Richard Mohs, Douglas Beauregard, Lynne Hughes, Cyndy Cordell, Allan Levey, M.D., Ph.D., Saima Rathore, Nicholas Seyfried, Erik Johnson, Jessie Nicodemus-Johnson, Joshua Christensen, and Robin […]
Global Alzheimer’s Platform Foundation Applauds Congressional Funding Increase for Alzheimer’s Research
Washington D.C., Jan 20, 2026, The Global Alzheimer’s Platform Foundation® (GAP) applauds the House and Senate Committees on appropriations releasing their final bipartisan FY2026 Labor–Health and Human Services–Education appropriations bill which increases funding for Alzheimer’s disease and other dementia research. “Congress’s bipartisan approval of increased funding for neurodegenerative research sends a powerful message to the millions of […]